Secretary of State Adrian Fontes said he is considering a run to replace Congressman Raul Grijalva, who passed away last week ...

If he runs, Fontes will have to resign as the state's top elections official. Gov. Katie Hobbs would pick his replacement.

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

Gov. Katie Hobbs has issued a proclamation calling for a special election to find a new representative for Arizona's 7th ...

CTD402 is a universal CAR-T cell product targeting CD7 derived from healthy donors and intended for the treatment of T-ALL/LBL. It is genetically modified to avoid fratricide, graft-versus-host ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

Researchers found that naturally-occurring CD7-negative T cells avoid self-destruction and are good effectors in CAR T therapy for T cell blood cancers. Deanna earned their PhD in cellular biology ...

Bioheng Therapeutics’ IND application for CTD402 gets US FDA clearance for CD7 UCAR T cell therapy in T-cell acute lymphoblastic leukemia: Boston Friday, March 7, 2025, 16:00 Hr ...

We remain diligently focused on the launch of our pivotal Phase 2 trial for WU-CART-007, the first CD7-targeted allogeneic CAR-T cell therapy. Jim's experience will be critical as we advance that ...

CTD402 is a universal CAR-T cell product targeting CD7 derived from healthy donors and intended for the treatment of T-ALL/LBL. It is genetically modified to avoid fratricide, graft-versus-host ...